The Pharmacological Management of Chronic Pain in Long-Term Care Settings: Balancing Efficacy and Safety

Consultant Pharmacist

Volumn 18, Issue SUPPL. A, 2003, Pages 4-18

  Argoff, Charles E ^a,b   Cranmer, Werry W ^c,d  

^a NORTH SHORE UNIVERSITY HOSPITAL   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Amer Bd of Psychiat and Neurology ^*  (United States)

^d UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

Chronic pain; Elderly; Long term care; Nursing home; Persistent pain; Pharmacological treatment; Undertreatment

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; ANALGESIC AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; CAPSAICIN; CARBAMAZEPINE; CLONAZEPAM; CODEINE; CYCLOOXYGENASE 2 INHIBITOR; DIPHENHYDRAMINE; ETIRACETAM; FENTANYL; FENTANYL CITRATE; GABAPENTIN; HYDROCODONE; HYDROMORPHONE; IBUPROFEN; LAMOTRIGINE; LIDOCAINE; METHADONE; MORPHINE SULFATE; MUSCLE RELAXANT AGENT; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; OXCARBAZEPINE; OXYCODONE; OXYMORPHONE; PARACETAMOL; PERCOCET; PHENYTOIN; TOPICAL AGENT; TOPIRAMATE; UNINDEXED DRUG; VALPROATE SEMISODIUM; VALPROIC ACID; ZONISAMIDE; ZYDONE;

ADDICTION; ANALGESIA; ATAXIA; BURNING SENSATION; CHRONIC PAIN; CLINICAL PHARMACY; CLINICAL TRIAL; COGNITIVE DEFECT; CONSTIPATION; DIPLOPIA; DIZZINESS; DROWSINESS; DRUG DEPENDENCE; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERANCE; DRUG USE; ENDOCRINE DISEASE; GASTROINTESTINAL TOXICITY; GERIATRIC PATIENT; HEART ARRHYTHMIA; HUMAN; HYPOTENSION; INAPPROPRIATE DRUG USE; LETHARGY; LIBIDO DISORDER; LIVER TOXICITY; LONG TERM CARE; LOW BACK PAIN; MENTAL DISEASE; NAUSEA; NEPHROTOXICITY; NEUROPATHIC PAIN; NURSING HOME; NYSTAGMUS; ORTHOSTATIC HYPOTENSION; PAIN ASSESSMENT; PHARMACIST; POSTHERPETIC NEURALGIA; PREVALENCE; PRURITUS; REVIEW; SEDATION; SIDE EFFECT; SLEEP DISORDER; SOMNOLENCE; SUSTAINED RELEASE PREPARATION; THROMBOCYTE DYSFUNCTION; UNDERTREATMENT; VISUAL IMPAIRMENT; VOMITING; XEROSTOMIA;

EID: 0842321061     PISSN: 08885109     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (72)

1. Census 2000 special tabulation, nursing home population: United States Census Bureau, 2000.
2. Bernabei R, Gambassi G, Lapane K et al. Management of pain in elderly patients with cancer. SAGE Study Group. Systematic Assessment of Geriatric drug use via Epidemiology. JAMA 1998;279:1877-82.
3. Won A, Lapane K, Gambassi G et al. Correlates and management of nonmalignant pain in the nursing home. SAGE Study Group. Systematic Assessment of Geriatric drug use via Epidemiology. J Am Geriatr Soc 1999;47:936-42.
4. Teno JM, Weitzen S, Wetle T, Mor V. Persistent pain in nursing home residents. JAMA 2001;285:2081.
5. Ferrell BA, Ferrell BR, Osterweil D. Pain in the nursing home. J Am Geriatr Soc 1990;38:409-14.
6. Ferrell BA, Ferrell BR, Rivera L. Pain in cognitively impaired nursing home patients. J Pain Symptom Manage 1995;10:591-8.
7. Jacox A, Carr DB, Payne R. New clinical-practice guidelines for the management of pain in patients with cancer. N Engl J Med 1994;330:651-5.
8. Douzjian M, Wilson C, Schults M et al. A program to use pain control medication to reduce psychotropic drug use in residents with difficult behavior. An of Long Term Care 1998;6:174-8.
9. Hitchcock LS, Ferrell BR, McCaffery M. The experience of chronic nonmalignant pain. J Pain Symptom Manage 1994;9:312-8.
10. Parmalee P, Smith B, Katz I. Pain complaints and cognitive status among elderly institution residents. J Am Geriatr Soc 1993;41:517-22.
11. McCaffery M, Beebe A. Pain: Clinical Manual for Nursing Practice. St. Louis, Mo: Mosby Co; 1989.
12. The management of chronic pain in older persons. AGS Panel on Chronic Pain in Older Persons. American Geriatrics Society. Geriatrics 1998;53(suppl 3):s8-s24.
13. Cox K, Pappagallo M. Contemporary and emergent pharmacological therapies for chronic pain: nonopioid analgesia. Expert Rev Neurotherapeutics 2001;1:81-91.
14. Baron R. Peripheral neuropathic pain: from mechanisms to symptoms. Clin J Pain 2000;16:s12-s20.
15. Bennett GJ. Update on the neurophysiology of pain transmission and modulation: focus on the NMDA-receptor. J Pain Symptom Manage 2000;19:s2-s6.
16. The management of persistent pain in older persons. J Am Geriatr Soc 2002;50:s205-s24.
17. Ferrell B. Pain The Merck Manual of Geriatrics, 2003.
18. McCaffery M, Pasero C. Pain: clinical manual. St. Louis, MO: Mosby; 1999.
19. Rowbotham MC, Twilling L, Davies PS et al. Oral opioid therapy for chronic peripheral and central neuropathic pain. N Engl J Med 2003;348:1223-32.
20. Gimbel JS, Richards P, Portenoy RK. Controlled-release oxycodone for pain in diabetic neuropathy: a randomized controlled trial. Neurology 2003;60:927-34.
21. Watson CP, Babul N. Efficacy of oxycodone in neuropathic pain: a randomized trial in postherpetic neuralgia. Neurology 1998;50:1837-41.
22. Dellemijn PL, van Duijn H, Vanneste JA. Prolonged treatment with transdermal fentanyl in neuropathic pain. J Pain Symptom Manage 1998;16:220-9.
23. Dionne RA. Additive analgesic effects of oxycodone and ibuprofen in the oral surgery model. J Oral Maxillofac Surg 1999;57:673-8.
24. Sunshine A, Olson NZ, O'Neill E et al. Analgesic efficacy of a hydrocodone with ibuprofen combination compared with ibuprofen alone for the treatment of acute postoperative pain. J Clin Pharmacol 1997;37:908-15.
25. Gammaitoni AR, Galer BS, Lacouture P et al. Effectiveness and safety of new oxycodone/acetaminophen formulations with reduced acetaminophen for the treatment of low back pain. Pain Med 2003;4:21-30.
26. Cancer pain relief and palliative care: report of the WHO Expert Committee. Technical report series 894. Geneva, Switzerland: World Health Organization; 1990.
27. Clinical practice guidelines: acute pain management: operative or medical procedures and trauma. Rockville, MD: Department of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research. AHCRP clearinghouse. AHCPR publication 92-0032.3, 1992.
28. Clinical practice guideline number 9: Management of cancer pain. AHCPR publication 94-0592. Rockville, MD: Department of Health and Research, 1994.
29. Principles of analgesic use in the treatment of acute pain and cancer pain, 4th ed. Skokie, Ill: American Pain Society; 1999.
30. Guay DR. Adjunctive agents in the management of chronic pain. Pharmacotherapy 2001;21:1070-81.
31. Dworkin R, Backonja M, Rowbotham M et al. Advances in neuropathic pain: diagnosis, mechanisms, and treatment recommedations. Arch Neuro 2003. In press.
32. Argoff CE, Targeted topical peripheral analgesics in the management of pain. Curr Pain Headache Rep 2003;7:34-8.
33. Rowbotham MC, Davies PS, Verkempinck C et al. Lidocaine patch: double-blind controlled study of a new treatment method for post-herpetic neuralgia. Pain 1996;65:39-44.
34. Galer BS, Rowbotham MC, Perander J et al. Topical lidocaine patch relieves postherpetic neuralgia more effectively than a vehicle topical patch: results of an enriched enrollment study. Pain 1999;80:533-8.
35. Galer BS, Jensen MP, Ma T et al. The lidocaine patch 5% effectively treats all neuropathic pain qualities: results of a randomized, double-blind, vehicle-controlled, three-week efficacy study with use of the neuropathic pain scale. Clin J Pain 2002;18:297-301.
36. Devers A, Galer BS. Topical lidocaine patch relieves a variety of neuropathic pain conditions: an open-label study. Clin J Pain 2000;16:205-8.
37. Dworkin R, Hart-Gouleau S, Gater B et al. Effectiveness and impact on quality of life of the lidocaine patch 5% in painful diabetic neuropathy patients with or without allodynia. Chicago, IL: American Pain Society; 2003.
38. Gimbel J, Galer B, Hale M et al. Impact of the lidocaine patch 5% on pain interference with quality of life when used in combination with gabapentin in three chronic pain states. Chicago, IL: American Pain Society; 2003.
39. Gimbel J, Hale M, Linn R. Lidocaine patch 5% in patients with acute/subacute and chronic low back pain: impact on pain intensity, pain relief, and pain interference. Chicago, IL: American Pain Society; 2003.
40. Gammaitoni A, Galer B, Burch F et al. Effectiveness and safety of the lidocaine patch 5% as monotherapy in patients with pain from osteoarthritis of the knee. American Society of Health-System Pharmacists; Atlanta, GA; 2002.
41. Watson CP. Topical capsaicin as an adjuvant analgesic. J Pain Symptom Manage 1994;9:425-33.
42. Keitel W, Frerick H, Kuhn U et al. Capsicum pain plaster in chronic non-specific low back pain. Arzneimittelforschung 2001;51:896-903.
43. Galeotti N, Di Cesare Mannelli L, Mazzanti G et al. Menthol: a natural analgesic compound. Neurosci Lett 2002;322:145-8.
44. Sindrup SH, Jensen TS. Efficacy of pharmacological treatments of neuropathic pain: an update and effect related to mechanism of drug action. Pain 1999;83:389-400.
45. Sidebottom A, Maxwell S. The medical and surgical management of trigeminal neuralgia. J Clin Pharm Ther 1995;20:31-5.
46. Magni G. The use of antidepressants in the treatment of chronic pain. A review of the current evidence. Drugs 1991;42:730-48.
47. Max MB, Lynch SA, Muir J et al. Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. N Engl J Med 1992;326:1250-6.
48. Sindrup SH, Bach FW, Madsen C et al. Venlafaxine versus imipramine in painful polyneuropathy: a randomized, controlled trial. Neurology 2003;60:1284-9.
49. Byas-Smith MG, Max MB, Muir J et al. Transdermal clonidine compared to placebo in painful diabetic neuropathy using a two-stage 'enriched enrollment' design. Pain 1995;60:267-74.
50. Zeigler D, Lynch SA, Muir J et al. Transdermal clonidine versus placebo in painful diabetic neuropathy. Pain 1992;48:403-8.
51. Max MB, Schafer SC, Culnane M et al. Assooation of pain relief with drug side effects in postherpetic neuralgia: a single-dose study of clonidine, codeine, ibuprofen, and placebo. Clin Pharmacol Ther 1988;43:363-71.
52. Shelley WB, Shelley ED. Aquadynia: noradrenergic pain induced by bathing and responsive to clonidine. J Am Acad Dermatol 1998;38:357-8.
53. Fromm GH, Aumentado D, Terrence CF. A clinical and experimental investigation of the effects of tizanidine in trigeminal neuralgia. Pain 1993;53:265-71.
54. Lake AE 3rd, Saper JR. Chronic headache: new advances in treatment strategies. Neurology 2002;59:s8-s13.
55. Fogelholm R, Murros K. Tizanidine in chronic tension-type headache: a placebo controlled double-blind cross-over study. Headache 1992;32:509-13.
56. Parsons CG. NMDA receptors as targets for drug action in neuropathic pain. Eur J Pharmacol 2001;429:71-8.
57. Nelson KA, Park KM, Robinovitz E et al. High-dose oral dextromethorphan versus placebo in painful diabetic neuropathy and postherpetic neuralgia. Neurology 1997;48:1212-8.
58. Amin P, Sturrock ND. A pilot study of the beneficial effects of amantadine in the treatment of painful diabetic peripheral neuropathy. Diabet Med 2003;20:114-8.
59. Kvarnstrom A, Karlsten R, Quiding H et al. The effectiveness of intravenous ketamine and lidocaine on peripheral neuropathic pain. Acta Anaesthesiol Scand 2003;47:868-77.
60. Browning R, Jackson JL, O'Malley PG. Cyclobenzaprine and back pain: a meta-analysis. Arch Intern Med 2001;161:1613-20.
61. Gardner-Nix J. Principles of opioid use in chronic noncancer pain. CMAJ 2003;169:1-11.
62. De Andres J, Cerda-Olmedo G, Valia JC et al. Use of botulinum toxin in the treatment of chronic myofascial pain. Clin J Pain 2003;19:269-75.
63. Wissel J, Muller J, Dressnandt J et al. Management of spasticity associated pain with botulinum toxin A. J Pain Symptom Manage 2000;20:44-9.
64. Loder E, Biondi D. Use of botulinum toxins for chronic headaches: a focused review. Clin J Pain 2002;18:s169-s176.
65. Ribeiro RA, Vale ML, Ferreira SH, Cunha FQ. Analgesic effect of thalidomide on inflammatory pain. Eur J Pharmacol 2000;391:97-103.
66. Peuckmann V, Strumpf M, Zenz M et al. Novel potential uses of thalidomide in the management of pain? A review of the literature. Schmerz 2003;17:204-10.
67. Ackerman LL, Follett KA, Rosenquist RW. Long-term outcomes during treatment of chronic pain with intrathecal clonidine or clonidine/opioid combinations. J Pain Symptom Manage 2003;26:668-77.
68. McCleane G. Topical application of doxepin hydrochloride, capsaicin and a combination of both produces analgesia in chronic human neuropathic pain: a randomized, double-blind, placebo-controlled study. Br J Clin Pharmacol 2000;49:574-9.
69. Wilder-Smith CH, Hill L, Spargo K et al. Treatment of severe pain from osteoarthritis with slow-release tramadol or dihydrocodeine in combination with NSAID's: a randomised study comparing analgesia, antinociception and gastrointestinal effects. Pain 2001;91:23-31.
70. Gimbel JS. Effect of lidocaine patch 5% on pain intensity and pain relief when used in combination with gabapentin in three chronic pain states. 19th Annual Meeting of the American Academy of Pain Medicaine. New Orleans, LA: Poster 522, 2003.
71. Beers MH, Ouslander JG, Rollingher I et al. Explicit criteria for determining inappropriate medication use in nursing home residents. UCLA Division of Geriatric Medicine. Arch Intern Med 1991;151:1825-32.
72. Beers MH. Explicit criteria for determining potentially inappropriate medication use by the elderly. An update. Arch Intern Med 1997;157:1531-6.